Vertebration's XYcor spine implant
This article was originally published in Clinica
Vertebration minimally-invasive XYcor spinal implant is designed to restore and maintain biomechanical integrity in the thoracolumbar spine following vertebrectomy or corpectomy in patients with spinal tumours or fractures. The device is an expandable implant, giving surgeons an extremely low-profile solution to the anatomic constraints of minimally-invasive surgery, said the Powell, Ohio firm. For insertion, it requires one-half the intradiscal entry point, but once deployed has a footprint comparable to traditional anterior interbody/vertebral body replacement devices.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.